New Osstic™ Bone Filler Enters Clinical Trial for Fractures
No efficacy or safety outcomes have been reported yet. The development moves into humans with MHRA approval for a...
Pacira Reveals Key Real-World Data from IGOR Registry Study
In real-world data from the Innovations in Genicular Outcomes Registry, patients who received liposomal bupivacaine during total knee arthroplasty...
FDA Lifts Clinical Hold on Intellia’s Pivotal ATTR-CM Study
FDA has lifted the clinical hold on Intellia’s Phase 3 MAGNITUDE trial of nexiguran ziclumeran in ATTR-CM after a...
EyePoint Launches Promising Phase 3 DURAVYU™ Trials for DME
EyePoint has begun dosing in two global Phase 3 trials, COMO and CAPRI, evaluating DURAVYU (vorolanib intravitreal insert) in...
Alzheimer’s Study Results Were Foreseeable, Not Astonishing
A 20-year follow-up of the NIH-funded, 2,800-participant ACTIVE study reports that less than 23 hours of speed-of-processing training delivered...
Aprea’s WEE1 Inhibitor Shows Surging, Positive Trial Data
Aprea reported a 50% reduction in target lesions at first assessment and an 87% drop in CA-125 (362 to...
TScan Completes Trial Enrollment, FDA Clears New Heme Drugs
Patients who fail to reach complete donor chimerism by month two after allogeneic transplant face a markedly higher relapse...
Aardvark Announces Voluntary Pause of Phase 3 HERO Trial
Aardvark Therapeutics has halted enrollment and dosing in its Phase 3 HERO trial and its open-label extension after reversible...
Cogent Highlights Bezuclastinib Summit Trial Data at AAAAI
Bezuclastinib delivered a mean −32.0-point reduction in total symptom score at 48 weeks in NonAdvanced systemic mastocytosis, a 56%...
First Participants Dosed in Scynexis’s SCY-247 Phase 1 Trial
SCYNEXIS has begun dosing in a Phase 1 single- and multiple-ascending dose study of its intravenous SCY-247, with initial...